CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Blood

Volumn 115, Issue 25, 2010, Pages 5232-5240

  Tyner, Jeffrey W ^a   Bumm, Thomas G ^a   Deininger, Jutta ^a   Wood, Lisa ^b   Aichberger, Karl J ^a,c   Loriaux, Marc M ^a,b   Druker, Brian J ^a,d   Burns, Christopher J ^e   Fantino, Emmanuelle ^e   Deininger, Michael W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Howard Hughes Medical Institute   (Australia)

^e Cytopia Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYT 387; CYTOKINE; FOCAL ADHESION KINASE 1; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; JANUS KINASE 1; JANUS KINASE 2; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; JAK1 PROTEIN, MOUSE; JAK2 PROTEIN, MOUSE; N (CYANOMETHYL) 4 (2 ((4 (4 MORPHOLINYL)PHENYL)AMINO) 4 PYRIMIDINYL)BENZAMIDE; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN KINASE INHIBITOR;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL LINE; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; GROWTH INHIBITION; HEMATOCRIT; HEMATOPOIETIC CELL; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; MOLECULE; MONOTHERAPY; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN SIZE; SYMPTOM; ANIMAL; BAGG ALBINO MOUSE; BLOOD DISEASE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETICS; HEMATOPOIESIS; IMMUNOLOGY; METABOLISM; MISSENSE MUTATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; JANUS KINASE 1; JANUS KINASE 2; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 77954680141     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-223727     Document Type: Article

References (29)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
4. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106(10):3377-3379.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
6. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66(23):11156- 11165.
7. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660.
8. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
9. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281. (Pubitemid 43801351)
10. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321-330. (Pubitemid 351446196)
11. Pardanani AD, Gotlib J, Jamieson C, et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 97.
12. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311-320. (Pubitemid 351446195)
13. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332-2338. (Pubitemid 44497517)
14. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132. (Pubitemid 41323513)
15. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991;77(3):587-593.
16. Tyner JW, Walters DK, Willis SG, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 2008;111(4):2238-2245.
17. Wong ET, Ngoi SM, Lee CG. Improved coexpression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Ther. 2002;9(5):337-344.
18. Verstovsek S, Kantarjian H, Pardanani A, et al. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). J Clin Oncol. 2008;26(suppl 15 ed):373s.
19. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709-715.
20. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-880. (Pubitemid 32743979)
21. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792. (Pubitemid 40271173)
22. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953. (Pubitemid 41713984)
23. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
24. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. (Pubitemid 46193073)
25. Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007;110(1):370-374. (Pubitemid 47026856)
26. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468-6472. (Pubitemid 44085597)
27. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989;3(5):1637-1643. (Pubitemid 19077641)
28. Jacobs-Helber SM, Roh KH, Bailey D, et al. Tumor necrosis factor-alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood. 2003;101(2):524-531. (Pubitemid 36077573)
29. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640-2653. (Pubitemid 40446252)